The trend toward more target therapy in pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The trend toward more target therapy in pancreatic ductal adenocarcinoma

Published:2024-05-23 Issue:7 Volume:24 Page:525-565
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Deiana Chiara¹,Agostini Margherita¹,Brandi Giovanni¹²,Giovannetti Elisa³⁴

Affiliation:

1. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

2. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

3. Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center (VUmc), Amsterdam, The Netherlands

4. Cancer Pharmacology Lab, Associazione Italiana per la Ricerca sul Cancro (AIRC) Start-Up Unit, Fondazione Pisana per la Scienza, Pisa, San Giuliano, Italy

Funder

KWF Dutch Cancer Society

Associazione Italiana per la Ricerca sul Cancro

Bennink Foundation

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2357802

Reference183 articles.

1. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

2. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

3. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

4. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

5. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP